|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes显示文摘AIM To assess for passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts(TIPS) and compare outcomes with maximally dilated TIPS.METHODS Polytetrafluoroethylene covered TIPS(Viatorr) from July 2002 to December 2013 were retrospectively reviewed at two hospitals in a single institution. Two hundred and thirty patients had TIPS maximally dilated to 10 mm(m TIPS), while 43 patients who were at increased risk for hepatic encephalopathy(HE), based on clinical evaluation or low pre-TIPS portosystemic gradient(PSG), had 10 mm TIPS sub-maximally dilated to 8 mm(sm TIPS). Group characteristics(age, gender, Model for End-Stage Liver Disease score, post-TIPS PSG and clinical outcomes were compared between groups, including clinical success(ascites or varices), primary patency,primary assisted patency, and severe post-TIPS HE. A subset of fourteen patients with sm TIPS underwent follow-up computed tomography imaging after TIPS creation, and were grouped based on time of imaging(< 6 mo and > 6 mo). Change in diameter and crosssectional area were measured with 3D imaging software to evaluate for passive expansion.RESULTS Patient characteristics were similar between the sm TIPS and m TIPS groups, except for pre-TIPS portosystemic gradient, which was lower in the sm TIPS group(19.4 mm Hg ± 6.8 vs 22.4 mm Hg ± 7.1, P = 0.01). Primary patency and primary assisted patency between sm TIPS and m TIPS was not significantly different(P = 0.64 and 0.55, respectively). Four of the 55 patients(7%) with sm TIPS required TIPS reduction for severe refractory HE, while this occurred in 6 of the 218 patients(3%) with m TIPS(P = 0.12). For the 14 patients with follow-up computed tomography(CT) imaging, the median imaging follow-up was 373 d. There was an increase in median TIPS diameter, median percent diameter change, median area, and median percent area change in patients with CT follow-up greater than 6 mo after TIPS placement compared to follow-up within 6 mo(8.45 mm, 5.58%, 56.04 mm^2, and 11.48%, respectively, P = 0.01).CONCLUSION Passive expansion of sm TIPS does occur but clinical outcomes of sm TIPS and m TIPS were similar. Sub-maximal dilation can prevent complications related to overshunting in select patients. | Michael C Hsu Charles N Weber S William Stavropoulos Timothy W Clark Scott O Trerotola Richard D Shlansky Goldberg Michael C Soulen Gregory J Nadolski | 2017 | World Journal of Hepatology2017，9，12： | 11 |
| 2 | Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B显示文摘AIM:To evaluate the long-term treatment outcomes of entecavir monotherapy in treatment naive patients in an Australian tertiary care setting. METHODS:A retrospective analysis of treatment naive patients receiving entecavir monotherapy through Westmead Hospital was performed.Patients were excluded if they had received previous treatment with another nucleoside or nucleotide analogue,were pregnant or less than 18 years old. RESULTS:Out of 336 patients,163 patients fulfilled the selection criteria.Range of follow up was 3-46 mo (mean 26 mo).134 patients(82.2%)had pre-treatment biopsies,with 26 patients(16.0%)demonstrating F3-4 fibrosis.In total,153 patients(93.9%)achieved at least Partial Virological Suppression(PVS),with 134 patients (82.2%)achieving complete virological suppression. The cumulative CVS and PVS rates at 36 mo were 82.1%and 96.4%,respectively.3 patients(1.8%)failed to achieve PVS,while 5 patients(3.0%)developed virological rebound.128 patients(78.5%)maintained CVS throughout follow up.Predictors of CVS included lower baseline DNA level(P=0.001),hepatitis B virus e antigen negative status(P=0.001)and increasing age at treatment(log rank 0.001).No significant adverse effects were reported necessitating cessation of entecavir. CONCLUSION:Entecavir monotherapy is efficacious and safe in an Australian tertiary care setting.Resistance and rebound rates are very low.This is similar to data from controlled and uncontrolled trials around the world. | Farzan Fahrtash-Bahin Viraj C Kariyawasam Timothy Gray Karen Byth Jacob George Mark W Douglas | 2013 | World Journal of Gastroenterology2013，19，5： | 5 |
| 3 | Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes 显示文摘 | Timothy C H Simon W D | 2011 | Diabetes Ther2011，2，3： | 1 |
| 4 | Evolving space-filling curves to distribute radial basis functions over an inputspace显示文摘 | Timothy D C | 1994 | IEEE Transactions on Neural Networks1994，5，： | 1 |
| 5 | Evolving space filling curves to distribute radial basis functions over an in- put space 显示文摘 | Bruce A W Timothy D C | 1994 | IEEE Transactions on Neural Net- works1994，，5： | 1 |
| 6 | Family caregiver burden: Results of a longitudinal study of breast cancer patients and their primary family caregivers 显示文摘 | Eva Q Dong C Timothy W | 2004 | CAMJ2004，170，12： | 1 |
| 7 | Tillage effects on soil hydraulic properties in space and time:State of the science显示文摘 | Mark W S Timothy R G James C A | 2008 | Soil and Tillage Research2008，99，1： | 1 |
| 8 | Transparent conducting Nnc oxide thin films doped with aluminum and molybdenum显示文摘 | JOEL N D TIMOTHY A G DAVID M W TERESA M B MATTHEW Y BOBBY T TIMOTHY J C | 2007 | Journal V-acuum Society Technology2007，25，4： | 1 |
| 9 | Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes显示文摘 | Shimareet Kumar Lazlo Krenacs Jeffrey Medeiros Kojo S.J Elenitoba-Johnson Timothy C Greiner Lynne Sorbara Douglas W Kingma Mark Raffeld Elaine S Jaffe | 1998 | Human Pathology1998，，4： | 1 |
| 10 | Family caregiver burden: Results of a longitudinal study of breast cancer patients and their principal caregivers显示文摘 | Eva G Doug C Timothy W | 2004 | Canadian Medical Association2004，170，12： | 1 |
| 11 | Novel ion exchange chromatographic method using con ductimetric detection显示文摘 | Hamish S Timothy S Stevens W C B | 1975 | Analytical Chemistry1975，47，11： | 1 |
| 12 | Freeze/thaw stress in Ceanothus of southern California chaparral显示文摘 | Frank W Ewers Michael C Lawson Timothy J Bowen | 2003 | Oecologia2003，，136： | 1 |
| 13 | Design of a PZT Bimorph Actuator Using a meta - model based Approach 显示文摘 | DAVID J C MARY I F TIMOTHY W S | 2002 | Transactions of the ASME2002，124，6： | 1 |
| 14 | Permafrost-associated natural gas hydrate occurrences on the Alaska North Slope显示文摘 | Timothy S C Myung W Lee Warren F | 2011 | Ma rine and Petroleum Geology2011，28，2： | 1 |
| 15 | Single nucleotide polyrnorphism discovery in rainbow trout by deep sequenc- ing of a reduced representation library显示文摘 | Cecilia C S Timothy P S Ralph T W | 2009 | BMC Genom2009，10，： | 1 |
| 16 | Stategic risk:an ordinal approach 显示文摘 | JAMES M C TIMOTHY W R | 1992 | Management Science1992，，12： | 1 |
| 17 | Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxietylike behavior in rats 显示文摘 | Smythe J W Murphy D Timothy C | 1997 | Pharmacol Biochem Behav1997，56，3： | 1 |
| 18 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 19 | Family earegiver burden: re- sults of a longitudinal study of breast cancer patients and their principal family caregivers显示文摘 | Eva G Dong C Timothy W | 2004 | CAMJ2004，170，12： | 1 |
| 20 | Tillage effects on soil hydraulic properties in space and time: State of the science 显示文摘 | Mark W S Timothy R G James C A | 2008 | Soil and Tillage Research2008，99，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员